Stay updated on Propranolol and Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Propranolol and Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Propranolol and Pembrolizumab in Melanoma Clinical Trial page
- CheckyesterdayChange DetectedThe page now displays the ClinicalTrials.gov record for the melanoma treatment study, including its eligibility criteria, locations, study design, outcomes, and registration details, instead of a 403 error.SummaryDifference53%

- Check8 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check15 days agoChange DetectedA sitewide NIH notice announces that agencies are using “Super Intelligence” in place of “Artificial Intelligence” during a transition and links to updates and FAQs.SummaryDifference1%

- Check22 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1; the study record still displays a 403 error.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record and site navigation with an access-denied screen, which prevents viewing the trial details.SummaryDifference19%

Stay in the know with updates to Propranolol and Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Propranolol and Pembrolizumab in Melanoma Clinical Trial page.